State Street’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-3,518,906
| Closed | -$63.3M | – | 3910 |
|
|
2020
Q2 | $63.3M | Buy |
3,518,906
+276,033
| +9% | +$3.84M | ﹤0.01% | 1284 |
|
|
2020
Q1 | $23.1M | Buy |
3,242,873
+16,171
| +0.5% | +$202K | ﹤0.01% | 1756 |
|
|
2019
Q4 | $77.1M | Buy |
3,226,702
+35,575
| +1% | +$981K | 0.01% | 1219 |
|
|
2019
Q3 | $85.6M | Sell |
3,191,127
-420,070
| -12% | -$11.8M | 0.01% | 1096 |
|
|
2019
Q2 | $98M | Buy |
3,611,197
+219,472
| +6% | +$6.88M | 0.01% | 1055 |
|
|
2019
Q1 | $118M | Sell |
3,391,725
-476,509
| -12% | -$13.7M | 0.01% | 911 |
|
|
2018
Q4 | $75.5M | Buy |
3,868,234
+285,591
| +8% | +$5.87M | 0.01% | 1077 |
|
|
2018
Q3 | $95.4M | Buy |
3,582,643
+754,064
| +27% | +$24.6M | 0.01% | 1109 |
|
|
2018
Q2 | $107M | Sell |
2,828,579
-222,726
| -7% | -$8.52M | 0.01% | 993 |
|
|
2018
Q1 | $99.7M | Buy |
3,051,305
+762,584
| +33% | +$33.5M | 0.01% | 1010 |
|
|
2017
Q4 | $111M | Sell |
2,288,721
-112,284
| -5% | -$5.68M | 0.01% | 965 |
|
|
2017
Q3 | $130M | Buy |
2,401,005
+315,167
| +15% | +$18.5M | 0.01% | 844 |
|
|
2017
Q2 | $117M | Buy |
2,085,838
+105,207
| +5% | +$4.21M | 0.01% | 869 |
|
|
2017
Q1 | $77.6M | Sell |
1,980,631
-35,821
| -2% | -$1.14M | 0.01% | 1081 |
|
|
2016
Q4 | $45.2M | Buy |
2,016,452
+34,027
| +2% | +$665K | ﹤0.01% | 1331 |
|
|
2016
Q3 | $45M | Buy |
1,982,425
+402,820
| +26% | +$9.46M | ﹤0.01% | 1263 |
|
|
2016
Q2 | $37.3M | Sell |
1,579,605
-140,395
| -8% | -$3.47M | ﹤0.01% | 1326 |
|
|
2016
Q1 | $35.1M | Buy |
1,720,000
+368,946
| +27% | +$11.7M | ﹤0.01% | 1343 |
|
|
2015
Q4 | $69.5M | Buy |
1,351,054
+53,626
| +4% | +$2.6M | 0.01% | 991 |
|
|
2015
Q3 | $55.3M | Sell |
1,297,428
-10,876
| -0.8% | -$525K | 0.01% | 1108 |
|
|
2015
Q2 | $59.6M | Buy |
1,308,304
+51,201
| +4% | +$2.06M | 0.01% | 1157 |
|
|
2015
Q1 | $47.7M | Buy |
1,257,103
+11,279
| +0.9% | +$387K | ﹤0.01% | 1268 |
|
|
2014
Q4 | $35.3M | Buy |
1,245,824
+689,289
| +124% | +$19.2M | ﹤0.01% | 1410 |
|
|
2014
Q3 | $14.1M | Buy |
556,535
+29,334
| +6% | +$773K | ﹤0.01% | 1974 |
|
|
2014
Q2 | $15.4M | Buy |
527,201
+365,999
| +227% | +$8.86M | ﹤0.01% | 1984 |
|
|
2014
Q1 | $4.17M | Sell |
161,202
-727
| -0.4% | -$19.4K | ﹤0.01% | 2675 |
|
|
2013
Q4 | $4.17M | Buy |
161,929
+39,086
| +32% | +$950K | ﹤0.01% | 2682 |
|
|
2013
Q3 | $3.29M | Buy |
122,843
+26,043
| +27% | +$620K | ﹤0.01% | 2768 |
|
|
2013
Q2 | $2.38M | Buy |
+96,800
| New | +$1.92M | ﹤0.01% | 2886 |
|
State Street's PTLA Position: Q3 2020 in Review
State Street sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 3,518,906 shares — an estimated $63.3M sold.
State Street first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $130M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- State Street reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- State Street sold 3,518,906 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $63.3M.
- State Street first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- State Street's Portola Pharmaceuticals, Inc. position peaked at $130M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on State Street's 13F filing for Q3 2020, filed 10 Nov 2020.